Cell and gene therapy-focused CDMO Andelyn Biosciences has extended its AAV Curator Platform offering with the Broad Institute's Stanton Lab CNS capsids.
The capsids were developed by researchers at the Broad Institute, and can be used to produce adeno-associated viruses (AAVs) that increase brain transduction and reduce tropism in peripheral organs.
Andelyn's novel agreement with the research institute is an extension of the MyoAAV plasmid deal the pair struck up in August 2024.
Under its terms, Andelyn will be able to use the Stanton Lab CNS capsids to perform R&D services for its clients who are developing cell and gene therapies.
Primarily, the CDMO will use the capsids to screen potential candidates and perform scale-up, as well as performing pre-clinical development work for IND-enabling studies.
Andelyn will also be able to sublicense them to clients for internal research purposes.
Notably, data suggests that transduction of the capsids can up to 6x more effective at targeting the cerebrum, while also being 13x more potent in transducing the neuroretina.
Chief Commerical Officer at Andelyn, Matt Niloff, commented: "Expanding our agreement with the Broad Institute to include these novel CNS capsids enables Andelyn to offer critical tools to our clients who are seeking to manufacture gene therapies for neurologic diseases."
"We’re excited by the potential to provide safer and more effective treatments for rare central nervous system diseases to patients in need of these critical treatments.”
